Gyre Therapeutics, Inc. GYRE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$9.86M-364% | —— | $5.94M+108% | $1.58M-65.3% | $3.73M-62.4% | ||
| $672K+25.6% | $656K+42.3% | $649K+45.8% | $641K+181% | $535K+28.9% | ||
| $2.58M+409% | $4.6M+711% | $1.15M+384% | $906K+5,563% | $507K+4,509% | ||
| -$16K— | -$2K— | -$1K— | —— | —— | ||
| -$8.57M-1,287% | $4.83M+321% | —— | —— | $722K— | ||
| $1.02M-34.1% | $1.21M+924% | $0-100% | $954K+32.7% | $1.54M+131% | ||
| $139K+893% | —— | $483K— | -$51K+15.0% | $14K+161% | ||
| $683K-84.6% | $2.38M— | -$3.51M-127% | —— | $4.44M+326% | ||
| $912K-83.5% | $509K+122% | -$398K0.0% | —— | $5.54M+264% | ||
| —— | -$11.75K-145% | -$11.75K+46.6% | -$11.75K-151% | -$11.75K-194% | ||
| $144K+106% | $261K— | —— | —— | -$2.27M-259% | ||
| —— | -$236K+89.5% | -$236K-41.3% | —— | —— | ||
| $3.18M+2,565% | —— | $4.68M— | $2.09M+138% | -$129K-104% | ||
| $178K+45.9% | $144K— | $668K-3.6% | $256K-82.4% | $122K-47.2% | ||
| $10.07M-10.0% | $4.24M— | —— | —— | $11.19M— | ||
| $6K+500% | $11K-92.0% | $0— | $18K-91.7% | $1K-98.0% | ||
| $5K-99.3% | $0-100% | $15K— | $23K— | $699K— | ||
| —— | —— | —— | —— | —— | ||
| -$3.06M-255% | —— | -$1.25M+47.8% | -$3.04M+63.2% | $1.97M+127% | ||
| $21K-95.9% | $318K— | $50K-86.6% | $1.48M+438% | $509K-22.6% | ||
| —— | —— | —— | $1.68M— | $121K— | ||
| $21K-98.4% | $318K-67.0% | $365K+12.7% | $22.35M+14,228% | $1.34M+104% | ||
| $285K+470% | $127K+150% | $117K— | $49K+163% | $50K+209% | ||
| $431K-86.7% | —— | $3.91M+1,793% | $21.45M+257% | $3.23M+187% | ||
| $1.21M-63.9% | $1.13M+48.2% | $687K+27.9% | $447K-92.3% | $3.36M+134% | ||
| —— | -$7K-103% | -$7K-103% | -$7K-103% | -$7K-103% | ||
| -$647K-34.0% | —— | —— | —— | -$483K— | ||
| $195K+3.7% | -$34K-148% | -$54K— | -$163K-254% | $188K+2,786% | ||
| —— | —— | —— | —— | $39K-32.8% | ||
| —— | —— | —— | —— | $39K-32.8% | ||
| -$738K-286% | -$87K+85.3% | -$531K— | -$300K-209% | -$191K+39.0% | ||
| -$21K-10.5% | -$20K-17.6% | -$19K— | -$19K— | -$19K— | ||
| $683K-84.6% | $2.38M— | -$3.51M-127% | —— | $4.44M+326% | ||
| —— | -$250+75.0% | -$250+99.9% | -$250-100% | -$250+95.8% | ||
| $144K+106% | $261K— | —— | —— | -$2.27M-259% | ||
| $912K-83.5% | $509K+122% | -$398K0.0% | —— | $5.54M+264% | ||
| —— | —— | —— | —— | $25K— | ||
| $217K+10.2% | $171K-13.6% | $206K+33.8% | $203K+1.0% | $197K+65.5% | ||
| —— | —— | —— | —— | —— | ||
| $5K-99.3% | $0-100% | $15K— | $23K— | $699K— | ||
| $12.95M+54.1% | $2.83M+102% | $0— | $2.78M-60.5% | $8.4M+19.4% | ||
| $6K+500% | $11K-92.0% | $0— | $18K-91.7% | $1K-98.0% | ||
| $285K+470% | $127K+150% | $117K— | $49K+163% | $50K+209% | ||
| -$89K+96.1% | -$263K-35.6% | $23K-89.9% | -$212K+92.7% | -$2.26M+47.4% | ||
| -$1.9M+15.2% | $4.85M+12.1% | $178K+183% | -$1.64M-3,046% | -$2.24M-6,909% | ||
| $1.21M-63.9% | $1.13M+48.2% | $687K+27.9% | $447K-92.3% | $3.36M+134% | ||
| $3M+1,296% | -$5.77M-114% | $4.01M— | $1.83M+126% | -$251K-109% | ||
| $3M+1,296% | -$5.77M-114% | $4.01M— | $1.83M+126% | -$251K-109% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Gyre Therapeutics, Inc. generate?
- Gyre Therapeutics, Inc. (GYRE) generated $9.8M in operating cash flow over the trailing twelve months.
- What is Gyre Therapeutics, Inc.'s free cash flow?
- After $1.2M of capital expenditures, Gyre Therapeutics, Inc.'s free cash flow was $3.1M over the trailing twelve months, up 142.4% year over year.
- Where does Gyre Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
